JP MORGAN/PUT/VERTEX PHARMACEUTICALS/345/0.1/17.01.25 | Real-time Bid/Ask 11:53:06 2024-07-11 am EDT | ||
| 0.26 EUR / 0.41 EUR | +15.52% |
|
| Current month | -29.27% | ||
| 1 month | -30.95% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-07-11 | 0.26 | -10.34% |
| 24-07-10 | 0.29 | -6.45% |
| 24-07-09 | 0.31 | -8.82% |
| 24-07-08 | 0.34 | -12.82% |
| 24-07-05 | 0.39 | -2.50% |
Delayed Quote Börse Stuttgart
Last update July 11, 2024 at 03:22 am EDT
More quotesStatic data
| Product type | Warrant Plain-Vanilla |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | J.P. Morgan |
| WKN | JL2516 |
| ISIN | DE000JL25168 |
| Date issued | 2023-05-04 |
| Strike | 345 $ |
| Maturity | 2025-01-17 (190 Days) |
| Parity | 10 : 1 |
| Emission price | 4.46 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.87 € |
|---|---|
| Lowest since issue | 0.26 € |
| Spread | 0.15 € |
| Spread % | 35.71% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
491.6
USD
Average target price
473.1
USD
Spread / Average Target
-3.77%
- Stock Market
- Warrants
- Warrant
